Values

plaquetteFR

Expertise

plaquetteFR

Humanism

plaquetteFR

Responsibility

Word from the leader

In a world where communication is increasingly based on the use of digital tools, the relationship between doctors and their patients must adapt to this evolution. The ambition of Thess Corporate is to ensure that this evolution is an opportunity and a progress to better care for and better secure patients during their treatment.

This is why we are fully invested in the research and development of digital medical devices that serve medical remote monitoring.

This medical activity, for 25 years, has proven that it facilitates the medical organization of the follow-up of an increasing number of patients who are less and less hospitalized. It also improves the patient's quality of life during their treatment with less stress to communicate with their doctor and an empowerment that allows them to be more engaged and active in their treatment. Medical remote monitoring also helps to reduce treatment-related morbidity.

In each R&D project, in each deployment of Thess Monitoring and Thess Device, we are proud to help doctors and their care teams to improve the medical service provided to their patients.

Timeline

2021

  • Creation of Thess Corporate by La Sas La Valériane

2022

  • Contribution by La Valériane of its IT branch of activity including the CE class 1 DM Thess Monitoring and the Thess Device research program with its patent.

2023

  • Commitment to the Beautify Clinical study (Medical remote monitoring for 6 months following breast surgery for patients undergoing cancer treatment)
  • Commitment to the Prolife clinical study (Medical remote monitoring for 18 months of cancer treatment for patients on oral therapy).
  • Usage experimentation of Thess Device in the USA (Mayo Clinic) and in France (Avignon Provence Cancer Institute)

2024

  • ISO 13485 certification of Thess Corporate.
  • Commitment to CE DM class 2a certification for Thess Monitoring according to MDR (UE) 2017/745

2025

  • Convergence certification of Thess Monitoring for its commercialization in France
  • Convergence certification for the operation of the generic nephrology line
  • Commitment to the Trace clinical study (Medical remote monitoring for 3 months of post-ambulatory surgery or ERAS pain management for patients with moderate to severe pain)
  • Usage experimentation of Thess Device in Canada (CHU Montreal) and in France (CHU Grenoble)